Stability of sulfadiazine oral liquids prepared from tablets and powder.

PURPOSE To assess the stability of sulfadiazine (SDZ) oral liquids prepared from tablets and powder at two temperatures. METHODS Solutions of SDZ 200 mg/mL were prepared from commercially available 500 mg tablets and powder in sterile water for irrigation. They were stored in amber glass bottles at 4 degrees C and 23 degrees C. The concentrations of SDZ were determined in duplicate by high-performance liquid chromatography at 0, 1, 3, 7 and 14 days. The initial and final pH of solutions was compared. The recovery of SDZ from tablets was determined. A loss exceeding 10% of the initial concentration of SDZ was considered excessive degradation. RESULTS The recovery of SDZ from tablets was 100 +/- 3%. The initial pH values were significantly different between solutions prepared from tablets and powder, 6.9 and 9.8 respectively. No significant difference was found between initial and final pH values for the two all formulations. Detectable change in odor was observed for the solutions stored at 23 degrees C. The solution prepared from powder was stable 3 days stored at 4 degrees C. Other formulations lost over 10% of the initial SDZ concentration within 2 days. CONCLUSIONS SDZ 200 mg/mL oral solution prepared from powder could be used to facilitate drug administration to very young children by nurses but by taking account of its fast degradation.

[1]  A. Leone,et al.  Congenital toxoplasmosis: 10-year follow up , 1995, European Journal of Pediatrics.

[2]  K. Vutova,et al.  Congenital toxoplasmosis: eye manifestations in infants and children , 2002, Annals of tropical paediatrics.

[3]  H. Qublan,et al.  Toxoplasmosis and habitual abortion , 2002, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[4]  P. Thulliez,et al.  Traitement de la toxoplasmose congénitale non sévère par sulfadiazine et pyriméthamine en continu pendant un an : à propos de 46 cas , 2002 .

[5]  J. Magny,et al.  [Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimethamine continuously during 1 year: apropos of 46 cases]. , 2002, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[6]  N. Furusawa,et al.  Matrix solid-phase dispersion extraction and high-performance liquid chromatographic determination of residual sulfonamides in chicken. , 2001, Journal of chromatography. A.

[7]  B. Stray-Pedersen,et al.  Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. , 1999, American journal of obstetrics and gynecology.

[8]  A. Berrebi,et al.  Termination of pregnancy for maternal toxoplasmosis , 1994, The Lancet.

[9]  F. Pratlong,et al.  Fetal diagnosis of toxoplasmosis in 190 women infected during pregnancy , 1994, Prenatal diagnosis.

[10]  N. Anaizi,et al.  Instability of aqueous captopril solutions. , 1993, American journal of hospital pharmacy.

[11]  C. Wilson,et al.  Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. , 1980, Pediatrics.

[12]  Martindale.,et al.  THE EXTRA PHARMACOPOEIA , 1937 .